Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of an experimental drug called
Elsamitrucin in people with non-Hodgkin's lymphoma and to see if it can shrink their tumors.
Elsamitrucin has not been approved by the Food and Drug Administration (FDA). However, the
FDA is permitting the use of this drug for this study.